ProQR Therapeutics
PRQR
37 hedge funds and large institutions have $181M invested in ProQR Therapeutics in 2015 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 13 reducing their positions, and 7 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 13
0.76% less ownership
Funds ownership: 47.17% → 46.41% (-0.76%)
3% less funds holding
Funds holding: 38 → 37 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
21% less capital inflows, than outflows
Capital inflows: $18.4M | Capital outflows: $23.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$11.1M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$3.52M |
| 3 |
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$837K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$725K |
| 5 |
D.E. Shaw & Co
New York
|
+$437K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Visium Asset Management
New York
|
-$6.02M |
| 2 |
Redmile Group
San Francisco,
California
|
-$4.42M |
| 3 |
Janus Henderson Investors US
Denver,
Colorado
|
-$3.73M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$2.95M |
| 5 |
Lombard Odier Asset Management (USA)
New York
|
-$1.51M |
PRQR Hedge Fund Activity: Q2 2015 in Review
37 of the 3,730 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2015, worth a combined $181M — down 25% from $241M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PRQR and 6 opened new positions — a net loss of 1 holder — while 13 trimmed existing stakes and 14 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $11.1M. The largest seller was Visium Asset Management, exiting entirely with an estimated $6.02M sold.
- 37 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2015, down from 38 in Q1 2015.
- Funds reported $181M of ProQR Therapeutics stock for Q2 2015, down 25% quarter-over-quarter.
- 6 funds opened new ProQR Therapeutics positions in Q2 2015 and 7 closed out, a net change of -1 holder.
- The largest ProQR Therapeutics buyer in Q2 2015 was Baker Bros. Advisors, an estimated $11.1M added.
- The largest ProQR Therapeutics seller in Q2 2015 was Visium Asset Management, an estimated $6.02M sold.
Based on aggregated 13F filings for Q2 2015.